Existing drugs—including Viagra, a shingles vaccine, and a treatment for ALS—have been identified by experts as leading candidates for repurposing against Alzheimer’s disease. A recent analysis of 80 potential treatments ranked these three as high-priority options for clinical trials, emphasizing the efficiency and cost-effectiveness of exploring existing compounds before developing entirely new drugs.
The Repurposing Approach
Drug repurposing—using already approved medications for new conditions—is faster, safer, and cheaper than traditional drug development. The analysis, conducted by a panel of 21 experts using a structured Delphi consensus method, suggests that these three drugs have enough existing evidence to justify further investigation for Alzheimer’s. This approach recognizes that many drugs have off-target effects that may be beneficial in treating other diseases.
The Top Three Candidates
- Sildenafil (Viagra): Originally used for erectile dysfunction, sildenafil relaxes blood vessels and has shown potential in reducing the buildup of toxic tau proteins in the brain—a hallmark of Alzheimer’s.
- Zostavax (Shingles Vaccine): The most promising candidate, the shingles vaccine appears to boost the immune system in ways that may protect against Alzheimer’s, although the exact mechanism is not yet fully understood.
- Riluzole (ALS Treatment): This drug prevents neuron death by altering biological pathways and reducing brain chemicals linked to neurodegeneration.
Why This Matters
Alzheimer’s disease remains a significant global health challenge, and current treatments are limited. The urgency to find effective therapies has led researchers to explore unconventional approaches, including repurposing existing drugs. The fact that these candidates have already been tested for safety in humans reduces the risks associated with clinical trials.
Next Steps
While the panel’s endorsement is encouraging, robust clinical trials are still needed to confirm whether these drugs can prevent or reverse Alzheimer’s in human patients. Researchers emphasize that this is only the beginning of a longer process.
“Beating dementia will take every avenue of research… Drug repurposing is a vital part of that mix.” — Anne Corbett, dementia researcher at the University of Exeter.
The complexity of Alzheimer’s pathology means there are many factors at play, and understanding how these drugs interact with the disease will be crucial for success.
Ultimately, while no definitive treatment yet exists, the identification of these three drugs as high-priority candidates offers a new avenue for research and a glimmer of hope in the fight against Alzheimer’s.
